161 related articles for article (PubMed ID: 8946471)
21. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Zanger UM; Fischer J; Raimundo S; Stüven T; Evert BO; Schwab M; Eichelbaum M
Pharmacogenetics; 2001 Oct; 11(7):573-85. PubMed ID: 11668217
[TBL] [Abstract][Full Text] [Related]
23. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.
Shimada T; Tsumura F; Yamazaki H; Guengerich FP; Inoue K
Pharmacogenetics; 2001 Mar; 11(2):143-56. PubMed ID: 11266079
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
25. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population.
Armstrong M; Fairbrother K; Idle JR; Daly AK
Pharmacogenetics; 1994 Apr; 4(2):73-81. PubMed ID: 8081414
[TBL] [Abstract][Full Text] [Related]
26. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
Douglas AM; Atchison BA; Somogyi AA; Drummer OH
Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
[No Abstract] [Full Text] [Related]
27. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype.
Daly AK; Fairbrother KS; Andreassen OA; London SJ; Idle JR; Steen VM
Pharmacogenetics; 1996 Aug; 6(4):319-28. PubMed ID: 8873218
[TBL] [Abstract][Full Text] [Related]
28. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.
Kubota T; Yamaura Y; Ohkawa N; Hara H; Chiba K
Br J Clin Pharmacol; 2000 Jul; 50(1):31-4. PubMed ID: 10886115
[TBL] [Abstract][Full Text] [Related]
29. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
30. Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population.
Mitsunaga Y; Kubota T; Ishiguro A; Yamada Y; Sasaki H; Chiba K; Iga T
Mutat Res; 2002 Aug; 505(1-2):83-5. PubMed ID: 12175908
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphism of CYP2D6 in the Japanese population.
Chida M; Yokoi T; Kosaka Y; Chiba K; Nakamura H; Ishizaki T; Yokota J; Kinoshita M; Sato K; Inaba M; Aoki Y; Gonzalez FJ; Kamataki T
Pharmacogenetics; 1999 Oct; 9(5):601-5. PubMed ID: 10591540
[TBL] [Abstract][Full Text] [Related]
32. The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients.
Topić E; Stefanović M; Ivanisević AM; Petrinović R; Curcić I
Clin Chim Acta; 2000 Jun; 296(1-2):101-9. PubMed ID: 10807974
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
[TBL] [Abstract][Full Text] [Related]
34. CYP2D6*36 gene arrangements within the cyp2d6 locus: association of CYP2D6*36 with poor metabolizer status.
Gaedigk A; Bradford LD; Alander SW; Leeder JS
Drug Metab Dispos; 2006 Apr; 34(4):563-9. PubMed ID: 16415111
[TBL] [Abstract][Full Text] [Related]
35. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
Petersen DD; Kong AN; Jorge LF; Nebert DW; Arias TD
Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Yokoi T; Kamataki T
Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
[TBL] [Abstract][Full Text] [Related]
37. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
Wang SL; Huang JD; Lai MD; Liu BH; Lai ML
Clin Pharmacol Ther; 1993 Apr; 53(4):410-8. PubMed ID: 8097442
[TBL] [Abstract][Full Text] [Related]
38. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.
Gaedigk A; Fuhr U; Johnson C; Bérard LA; Bradford D; Leeder JS
Pharmacogenomics; 2010 Jan; 11(1):43-53. PubMed ID: 20017671
[TBL] [Abstract][Full Text] [Related]
39. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
Kagimoto M; Heim M; Kagimoto K; Zeugin T; Meyer UA
J Biol Chem; 1990 Oct; 265(28):17209-14. PubMed ID: 2211621
[TBL] [Abstract][Full Text] [Related]
40. Genotype and allele frequency of CYP2D6 in Tamilian population.
Adithan C; Gerard N; Naveen AT; Koumaravelou K; Shashindran CH; Krishnamoorthy R
Eur J Clin Pharmacol; 2003 Oct; 59(7):517-20. PubMed ID: 12942225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
